BL-M02D1 vs Sacituzumab Tirumotecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: TROP2 · full Non-Small Cell Lung Cancer pipeline
BL-M02D1
Developed by Sichuan Baili Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Sacituzumab Tirumotecan
Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners
NCT05870319 · Phase 3 · active, not recruiting
This is a randomized, adequately sized (n=376) trial with an active comparator (standard chemotherapy) and a hard clinical endpoint (progression-free survival), and the result was strongly positive favoring the drug. However, the study was conducted open-label with no blinding, which limits confidence in a design that would otherwise support a top-tier grade despite the clear and statistically robust result.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2026 · NCT06448312 (registry estimate)
Reported efficacy
Progression-free survival (PFS) (From baseline until disease progression, death, or other protocol defined reason,up to approximately 36 months): OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001 (met)
Result source: NCT05870319
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BL-M02D1 | Sacituzumab Tirumotecan |
|---|---|---|
| PFS, median | —Not reported | —Trial running · NCT05870319 |
| OS, median | —Not reported | —Trial running · NCT05870319 |
| ORR | —Not reported | —Trial running · NCT05870319 |
| Duration of response, median | —Not reported | —Trial running · NCT05870319 |
PFS, median
- BL-M02D1
- —Not reported
- Sacituzumab Tirumotecan
- —Trial running · NCT05870319
OS, median
- BL-M02D1
- —Not reported
- Sacituzumab Tirumotecan
- —Trial running · NCT05870319
ORR
- BL-M02D1
- —Not reported
- Sacituzumab Tirumotecan
- —Trial running · NCT05870319
Duration of response, median
- BL-M02D1
- —Not reported
- Sacituzumab Tirumotecan
- —Trial running · NCT05870319
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
BL-M02D1: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BL-M02D1's landscape · Sacituzumab Tirumotecan's landscape